Navigation Links
ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met,Inhibitor, for Oral Presentation at ASCO

WOBURN, Mass.--(BUSINESS WIRE)--Mar 14, 2007 - ArQule, Inc. (NASDAQ: ARQL) today announced that the American Society of Clinical Oncology (ASCO) has accepted for oral presentation the Company's abstract for ARQ 197 (A Phase 1 Dose Escalation Study of ARQ 197, a Selective Inhibitor of the c-Met Receptor in Patients with Metastatic Solid Tumors) at the 43rd ASCO Annual Meeting, June 1-5, 2007, in Chicago. This presentation will describe findings from a Phase 1 trial with ARQ 197, a selective, small molecule inhibitor of the c-Met receptor tyrosine kinase, in cancer patients with a broad range of metastatic solid tumor types who had failed prior treatment regimens.

In addition, abstracts describing protocol design and patient recruitment as of January, 2007 in the Company's ongoing Phase 2 trials with ARQ 501 in leiomyosarcoma and pancreatic cancer have been accepted for publication in the ASCO Proceedings. The Company expects to announce further results from these trials, as well as from a Phase 2 trial in head and neck cancer, in mid-2007. ARQ 501 is an activator of the DNA damage response/checkpoint pathway regulated by the E2F-1 regulatory protein and is the lead product from the Company's Activated Checkpoint Therapy (ACT) platform.

The American Association for Cancer Research (AACR) has accepted eleven abstracts submitted by the Company in connection with AACR's 2007 Annual Meeting, April 14-18, 2007, in Los Angeles. The AACR abstracts are based on pre-clinical studies that cumulatively provide a rationale for the company's approaches to cancer therapy as embodied in its c-Met inhibition and DNA damage response/checkpoint activation platforms. They represent a broad scope of findings from in vitro (cell line) and in vivo (animal) experiments.

Consistent with the disclosure policies mandated by ASCO and AACR, ArQule will summarize the contents of these studies at the time the complete abstracts
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:5/22/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage ... regeneration, today announced that J.J. Finkelstein , chief ... corporate overview at two upcoming investor conferences. ... th Annual Microcap Conference on Thursday May 28, ... at 11:00 am EDT.  A webcast will be available ...
(Date:5/22/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... the results of the Company,s 72-patient, placebo-controlled Phase ... for the treatment of dry eye patients using ... model.  The exploratory study was completed in late ... by the Company in a press release, identify ...
(Date:5/22/2015)... May 20, 2015 Research and Markets( ... "Guide to Prepare Application Dossiers for Oversea ... Edition) " report to their offering. ... of segment market of the most growth potentiality, ... device manufacturers and producers to penetrate such market. ...
Breaking Medicine Technology:RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3
... This Week , a leading industry publication, has honored Amedica®/US ... for Spine Care in 2010 . Amedica/US Spine, ... unique silicon nitride (SiN) ceramic technologies, received recognition in the ... Valeo® AL Lumbar Spacer and Best New Technology in ...
... CareTech Solutions, an information technology and Web products ... hospitals, announced today that the Detroit Medical Center ... document imaging solution, iDoc™, for the eight-facility integrated ... "As the largest healthcare provider in southeast Michigan, ...
Cached Medicine Technology:Two Amedica®/US Spine® Implant Products Receive Best New Technology Awards from Orthopedics This Week 2Detroit Medical Center Chooses CareTech Solutions' Document Imaging System 2
(Date:5/24/2015)... 24, 2015 ProPin is a set ... Pro X. Utilize ProPin to pin point locations on a ... , ProPin allows users to choose from 30 simplistic ... With on-screen controls, video editors can easily manipulate ProPin presets ... and mark with absolute ease. , Using ProPin is easy, simply ...
(Date:5/24/2015)... May 24, 2015 Medicx Media ... Media strategy executive Jay Krihak as its head ... to ramp up its expertise and leadership position ... Pharmaceutical and Health sectors. , Krihak is an ... Most recently, Krihak led sales planning teams for ...
(Date:5/24/2015)... A report out just last month ... option for avoiding cardiovascular disease is exercise and maintaining ... single most powerful predictor of death and survival, even ... family history of premature death -- a finding that ... fitness. , The Importance of Cardiovascular Screening , The ...
(Date:5/23/2015)... On May 13, Nithyananda Yoga Foundation ... yogic power learned through meditation and initiation at Special ... India. , Yogamaatha, a nine-year-old girl from North Carolina, ... professionals attending the 2015 Business Advocacy Summit at Capitol ... , In a demonstration that lasted three hours, ...
(Date:5/23/2015)... (PRWEB) May 23, 2015 With the ... businesses, are finding it increasingly difficult to provide their ... fail to provide adequate insurance for employees stand to ... been such an integral part of a business’s success ... healthcare for businesses, Online USA Doctors has created a ...
Breaking Medicine News(10 mins):Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Medicx Media Solutions Expands Executive Team 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 3Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3
... BOCA RATON, Fla., Oct. 16 Although stem cells ... around for quite some time. In today,s advanced ... many orthopedic conditions including osteoarthritis of the hip knee ... including rotator cuff tears, and various back conditions ...
... Blood-lead Tests to Pregnant Women and Young Children , ... today reminded Pennsylvania parents to test young children for ... Week, Oct. 18-24. , "Parents and caregivers need ... tested for lead poisoning," said Secretary of Health Everette ...
... and the WINFOCUS Society are founding a new ... international, peer-reviewed journal will serve as the official ... Critical UltraSound).,Volume 1, Number 1, will be published ... Ultrasound Journal is designed for clinicians and ...
... ... from BCS Global and Polycom help customers transform their business, improve collaboration, enhance ... ... Networks Limited ( www.bcsglobal.com ), a leading worldwide managed service provider of videoconferencing ...
... (NYSE: MED ), a provider of leading clinically proven, ... "America,s 200 Best Small Companies" by Forbes magazine. ... Medifast, advancing to number 16 on the list this year ... Forbes states, "Our list of the 200 Best Small Companies ...
... YORK, Oct. 16 HMS today announced that the Illinois ... a two-year contract to provide onsite post-payment review of hospital ... The scope of work will be performed by Permedion, Inc., ... support the state,s goal of consistent review of hospital claims ...
Cached Medicine News:Health News:Stem Cell and PRP Therapy for Orthopedic Conditions 2Health News:Stem Cell and PRP Therapy for Orthopedic Conditions 3Health News:Pennsylvania Observes National Lead Poisoning Prevention Week 2Health News:Springer and WINFOCUS found new journal 2Health News:BCS Global Completes Polycom Telepresence VNOC (Video Network Operations Center) Provider Program 2Health News:BCS Global Completes Polycom Telepresence VNOC (Video Network Operations Center) Provider Program 3Health News:Medifast, Inc. Named by Forbes as One of 'America's 200 Best Small Companies' 2Health News:Medifast, Inc. Named by Forbes as One of 'America's 200 Best Small Companies' 3
... motor is the first true high-speed, high-torque touch ... is comparable to Legend Gold and runs at ... lever design provides ergonomic positioning and true variable ... Classic, the Legend Gold Touch is also smaller, ...
... Retractors for image dependent ... exposure on large patients. ... exposure during image guided ... be accessorized for use ...
Fortitude as a unique complement to the spinal concepts family of products....
Fortitude as a unique complement to the spinal concepts family of products....
Medicine Products: